Doctors find a more effective treatment for convergence insufficiency
Findings from a study conducted by optometrists from the Nova Southeastern University have concluded that a combination of in-office therapy and at-home treatment can be the most effective solution to treat a common childhood eye problem, convergence insufficiency. Children in this condition can not point their eyes together accurately. This causes eye strain. Patients see double. Traditional treatment of this condition has been home-based only. This study emphasizes that if a trained therapist provides office-based treatment along with at-home therapy, results will be better.

Researchers at the University of Montreal and St. Justine Hospital have identified a new receptor called GPR91 that can cure a number of eye diseases in diabetics, premature babies and the elderly by activating growth of blood vessels. The study is the first of its kind to show how ganglion cells that need oxygen to nourish produce blood vessels to feed themselves. Doctors have expressed their concern about the uncontrolled growth of blood vessels that can eventually cut the retina off the back of the eye causing vision loss. They are, now, working on various aspects of the study such as the receptor’s ability to drive the formation of blood networks and blocking GPR91 to stop tumor growth.
Indian scientists, in a recently conducted research, have found that the turmeric spice (obtained from the rhizome of the Curcuma longa plant) can prove beneficial in the blockage of a biological pathway which leads to the progression of diabetic retinopathy, a complication that can cause blindness, if not treated at the right stage. A study showing that the incidence of diabetic retinopathy was much lower in Indians as compared to Europeans made the researchers curious about the ingredients of Indian diet that were helpful in preventing the disease. Curcumin’s anti-angiogenic effects against cancer, the scientists guessed, may also curb the growth of new blood vessels in the retina.
The U.S. Food and Drug Administration has given the pre-market approval to
Three recent studies conducted to examine the role of